EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer

Chan D K Nguyen, Benjamín A Colón-Emeric, Shigekazu Murakami, Mia N Y Shujath, Chunling Yi

Cell Reports · 2024-05 · 43 (5) · 114176

DOI: 10.1016/j.celrep.2024.114176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2024-05. Verfasst von Chan D K Nguyen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Drug Resistance, Neoplasm, Epigenesis, Genetic, Pancreatic Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-MethyltransferasesDrug Resistance, NeoplasmEpigenesis, GeneticPancreatic NeoplasmsGemcitabineDeoxycytidineRepressor ProteinsHumansCell Line, TumorAnimalsMiceCarcinoma, Pancreatic DuctalGene Expression Regulation, NeoplasticCellular Reprogramming

Stichwörter der Autor:innen

BACH1CP: CancerMAFFPRMT1chemoresistanceepigenetic reprogrammingpancreatic cancer

Substanzen

Protein-Arginine N-MethyltransferasesGemcitabineDeoxycytidinePRMT1 protein, humanRepressor Proteins

Autor:innen und Institutionen

  • Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
  • Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. Electronic address: cy232@georgetown.edu.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • NCI

Zitieren

APA

Nguyen, C. D. K., Colón-Emeric, B. A., Murakami, S., Shujath, M. N. Y., & Yi, C. (2024). PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer. Cell Reports, 43(5), 114176. https://doi.org/10.1016/j.celrep.2024.114176

Vancouver

Nguyen CDK, Colón-Emeric BA, Murakami S, Shujath MNY, Yi C. PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer. Cell Reports. 2024;43(5):114176. doi:10.1016/j.celrep.2024.114176

BibTeX
@article{Nguyen2024,
  author = {Nguyen, Chan D K and Colón-Emeric, Benjamín A and Murakami, Shigekazu and Shujath, Mia N Y and Yi, Chunling},
  title = {PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer},
  journal = {Cell Reports},
  year = {2024},
  volume = {43},
  number = {5},
  pages = {114176},
  doi = {10.1016/j.celrep.2024.114176}
}
Kostenlos starten →